Equities

Cytek Biosciences Inc

Cytek Biosciences Inc

Actions
  • Price (USD)6.71
  • Today's Change0.08 / 1.21%
  • Shares traded684.00k
  • 1 Year change-21.89%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.

  • Revenue in USD (TTM)193.01m
  • Net income in USD-12.15m
  • Incorporated2014
  • Employees676.00
  • Location
    Cytek Biosciences Inc47215 LAKEVIEW BOULEVARDFREMONT 94538United StatesUSA
  • Websitehttps://cytekbio.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fulgent Genetics Inc289.21m-167.83m646.03m1.18k--0.5661--2.23-5.64-5.649.7138.310.2207--5.57244,267.70-13.3716.70-14.2518.3736.1267.89-60.5929.06----0.00480.00-53.2768.41-217.03--57.08--
SI-Bone Inc138.89m-43.34m649.64m344.00--3.80--4.68-1.13-1.133.624.160.7161.576.52403,738.40-22.34-27.88-25.24-30.9478.7885.03-31.20-51.098.15--0.1756--30.5220.1929.25--52.62--
Orthopediatrics Corp148.73m-20.97m682.23m247.00--1.80--4.59-0.9251-0.92516.5616.130.34330.40735.01602,153.90-4.84-5.40-5.28-5.9374.8075.09-14.10-15.922.90--0.026--21.6220.91-1,767.25--28.29--
Perspective Therapeutics Inc8.17m-25.10m702.39m88.00--3.41--85.96-0.1012-0.10120.03510.3520.09444.915.5592,852.27-29.01---31.19--22.96---307.18--2.55--0.0173--------------
Varex Imaging Corp877.80m44.60m715.78m2.30k26.271.269.060.81540.67120.671216.6514.010.72451.955.90365,750.003.720.99134.321.1832.3731.705.141.362.372.850.4322--3.962.9359.0818.880.2924--
Silk Road Medical Inc177.13m-55.74m732.96m474.00--4.85--4.14-1.44-1.444.563.860.66222.048.52373,700.40-20.84-29.02-23.22-32.9871.7572.91-31.47-46.846.97--0.3335--27.7738.66-1.33---7.92--
Embecta Corp1.12bn55.30m742.77m2.20k13.44--8.260.66180.95980.959819.47-13.780.92962.5719.35510,181.804.58--6.44--66.55--4.93--1.751.671.94---0.7703---68.52------
Treace Medical Concepts Inc187.12m-49.53m763.29m516.00--5.53--4.08-0.8154-0.81543.082.230.91071.455.56362,631.80-24.10---29.51--81.20---26.47--3.76--0.2776--31.92---15.68------
Atrion Corp169.33m19.41m788.41m712.0040.653.2522.854.6611.0211.0296.13138.010.64441.447.21237,817.407.3911.967.8512.6236.8441.9911.4619.052.5792.920.0042.42-7.732.12-44.55-10.744.9811.27
BioLife Solutions Inc143.27m-66.43m836.24m409.00--2.47--5.84-1.52-1.523.287.480.3322.465.45350,298.30-15.40-13.76-17.12-15.0432.6336.76-46.36-42.991.83-30.520.0733---11.4348.6552.49--86.35--
Cytek Biosciences Inc193.01m-12.15m867.36m676.00--2.20--4.49-0.0887-0.08871.433.010.38071.533.68285,523.70-2.40---2.67--56.69---6.29--5.89--0.0056--17.67---571.58------
Artivion Inc354.00m-30.57m891.70m1.50k--3.15--2.52-0.7496-0.74968.686.860.45531.605.30236,002.70-3.95-2.20-4.24-2.3664.7465.51-8.67-5.343.430.68090.5246--12.826.14-60.09--5.13--
Avanos Medical Inc673.30m-9.90m919.46m3.77k--0.743225.401.37-0.2092-1.3214.4326.770.3871.664.73178,546.80-0.5691-0.6527-0.6473-0.733856.3954.45-1.47-1.601.384.270.1196---1.580.6357-146.05---18.37--
Paragon 28 Inc216.39m-47.84m986.59m463.00--5.55--4.56-0.5816-0.58162.642.150.72760.54845.77---16.09---20.14--79.85---22.11--2.30-7.220.3832--19.30--28.94------
Pacific Biosciences of California Inc200.52m-306.74m996.78m796.00--1.42--4.97-1.21-1.210.79072.620.11422.707.24251,910.80-17.46-16.19-19.45-17.8128.0337.35-152.97-136.217.21-22.450.5601--56.2920.592.39--36.68--
Data as of Mar 28 2024. Currency figures normalised to Cytek Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

48.36%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Dec 202316.62m12.26%
Brown Capital Management LLCas of 31 Dec 202312.02m8.87%
The Vanguard Group, Inc.as of 31 Dec 202311.58m8.54%
RA Capital Management LPas of 31 Dec 20236.81m5.02%
HHLR Advisors Ltd.as of 31 Dec 20236.66m4.91%
SSgA Funds Management, Inc.as of 31 Dec 20234.00m2.95%
New York State Common Retirement Fundas of 31 Dec 20232.95m2.18%
Geode Capital Management LLCas of 31 Dec 20232.46m1.81%
Wellington Management Co. LLPas of 31 Dec 20231.29m0.95%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 20231.18m0.87%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.